Pfizer Inc.

Latest Pfizer Inc. Items
  • FDA OKs generic versions of pain pill Celebrex

    The Food and Drug Administration on Friday approved the first generic versions of Pfizer's anti-inflammatory painkiller Celebrex.


  • FILE - This Friday May 2, 2014 file photo shows an exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London. The board of AstraZeneca has rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, Monday May 19, 2014, a decision that has caused a sharp slide in the U.K. company's share price as investors think it effectively brings an end to the protracted and increasingly bitter takeover saga. (AP Photo/Matt Dunham, File)

    AstraZeneca rejects $119 billion offer from Pfizer

    The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.


  • Pfizer ups offer for AstraZeneca again, to $119B

    U.S. drugmaker Pfizer said Sunday that it has raised its offer for British rival AstraZeneca for a third time, hiking its stock-and-cash offer by 15 percent to $118.8 billion, or 70.73 billion pounds.


  • Pfizer seeks early approval for breast cancer drug

    Pfizer Inc. said Friday that the Food and Drug Administration will let the drugmaker apply for approval of its heavily touted experimental breast cancer medicine based on midstage patient testing results.


  • Pfizer CEO responds to governors on AstraZeneca

    The CEO of drugmaker Pfizer Inc. is telling the governors of Delaware and Maryland that it's premature to speculate about the potential jobs impact of a merger with British rival AstraZeneca PLC.


  • 2 governors express concerns to Pfizer

    The governors of Maryland and Delaware are voicing concern about Pfizer Inc.'s efforts to acquire AstraZeneca PLC.


  • Pfizer 1Q profit drops 15 pct due to lower sales

    Despite sharply lower expenses and taxes, Pfizer Inc.'s first-quarter profit dropped 15 percent, due to cheaper generic competition for multiple medicines and some promotion partnerships with other drugmakers ending.


  • An exterior view of the Two Kingdom Street building which houses the headquarters of AstraZeneca, in the Paddington area of London, Friday, May 2, 2014.  The board of pharmaceutical company AstraZeneca on Friday rejected drug maker Pfizer's sweetened takeover offer. Pfizer earlier in the day said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on a previous bid. The offer values AstraZeneca at $106 billion. (AP Photo/Matt Dunham)

    AstraZeneca rejects sweetened Pfizer takeover bid

    Pharmaceutical giant Pfizer said Friday that it hasn't given up on a deal after British drugmaker AstraZeneca flatly rejected its latest takeover bid, worth $106 billion.


  • Pfizer still pursuing AstraZeneca after 2nd rebuff

    Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.


Happening Now